L-Tyrosine

In the clinical intervention of chronic diseases such as mood disorders and hypothyroidism, the value of amino acid nutritional supplements and metabolism-regulating drugs is increasingly prominent. L-tyrosine is a non-essential aromatic amino acid and a key precursor for the human body to synthesize neurotransmitters and hormones such as dopamine, norepinephrine and thyroxine. It can alleviate symptoms such as low mood and inattention by regulating the level of monoamine neurotransmitters, and at the same time can fill the nutritional gap of people with tyrosine metabolism defects. It is not only suitable for the adjuvant treatment of depression and tyrosinemia, but also can be used as a raw material of nutritional supplement preparations for people under stress, and is also widely used in the field of functional food additives.At present, the global L-tyrosine market size has exceeded USD 320 million, and the compound annual growth rate from 2023 to 2028 is expected to remain at 5.7%. The demand growth mainly comes from two downstream fields: pharmaceutical nutritional preparations and sports nutrition food. The competitive landscape is characterized by a high concentration of production capacity. Chinese enterprises account for nearly 70% of the global API supply share. Compound nutritional preparations containing tyrosine in the domestic centralized procurement catalog have covered 11 provinces. The demand of downstream preparation enterprises for APIs with high purity and low impurity content continues to rise, and the bargaining power of compliant API suppliers meeting the ICH Q7 standard has increased significantly.As a mature amino acid API, L-tyrosine has no single original research enterprise. At present, USP, EP, JP and Chinese Pharmacopoeia all include its API quality standards. In China, more than 30 enterprises have obtained CDE registration for their L-tyrosine APIs (with more than 20 A-status registration numbers). More than 120 corresponding products such as oral preparations and compound amino acid preparations for injection have been approved for marketing. The compound patent has entered the public domain without patent restrictions. (Data as of October 2024, please refer to the official CDE website for the latest information)CATO provides a full set of L-tyrosine impurity reference standards, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. They meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can meet the full-process R&D needs such as API quality research and preparation consistency evaluation.

目前全球L-酪氨酸市场规模已超3.2亿美元，2023-2028年复合年增长率预计保持在5.7%，需求增长主要来自医药营养制剂、运动营养食品两大下游领域。竞争格局呈现产能高度集中特征，中国企业占据全球近70%的原料药供应份额，国内集采目录中含酪氨酸的复方营养制剂已覆盖11个省份，下游制剂企业对高纯度、低杂质含量的原料药需求持续提升，符合ICH Q7标准的合规API供应商议价能力明显增强。

L-酪氨酸作为成熟的氨基酸类原料药，暂无单一原研企业，目前USP、EP、JP及中国药典均收载其原料药质量标准，国内已有超30家企业的L-酪氨酸原料药通过CDE登记（A状态登记号超20个），对应的口服制剂、注射用复方氨基酸制剂等品种已有120余个获批上市，化合物专利已进入公共领域无专利限制。（数据截至2024年10月，最新请以CDE官网为准）

CATO/佳途科技提供L-酪氨酸全套杂质标准品，大部分产品现货供应，现货产品16:00前下单当天发货，符合中国药典、FDA等多法规合规要求，可满足原料药质量研究、制剂一致性评价等全流程研发需求。